SG Americas Securities LLC Takes Position in Cogent Biosciences, Inc. $COGT

SG Americas Securities LLC bought a new position in Cogent Biosciences, Inc. (NASDAQ:COGT) during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 25,905 shares of the technology company’s stock, valued at approximately $372,000.

A number of other large investors have also bought and sold shares of COGT. Vestal Point Capital LP raised its position in Cogent Biosciences by 2.7% in the 2nd quarter. Vestal Point Capital LP now owns 3,080,000 shares of the technology company’s stock valued at $22,114,000 after purchasing an additional 80,000 shares during the last quarter. Geode Capital Management LLC increased its stake in shares of Cogent Biosciences by 10.6% in the second quarter. Geode Capital Management LLC now owns 2,672,113 shares of the technology company’s stock valued at $19,189,000 after buying an additional 256,259 shares in the last quarter. Saturn V Capital Management LP raised its holdings in shares of Cogent Biosciences by 55.2% in the second quarter. Saturn V Capital Management LP now owns 2,297,524 shares of the technology company’s stock valued at $16,496,000 after buying an additional 817,504 shares during the last quarter. Frazier Life Sciences Management L.P. lifted its position in Cogent Biosciences by 85.2% during the 2nd quarter. Frazier Life Sciences Management L.P. now owns 1,734,601 shares of the technology company’s stock worth $12,454,000 after buying an additional 798,025 shares in the last quarter. Finally, Nantahala Capital Management LLC grew its holdings in Cogent Biosciences by 96.3% during the 2nd quarter. Nantahala Capital Management LLC now owns 1,655,689 shares of the technology company’s stock worth $11,888,000 after acquiring an additional 812,200 shares during the last quarter.

Cogent Biosciences Stock Performance

Shares of Cogent Biosciences stock opened at $36.68 on Monday. The firm has a fifty day moving average of $38.05 and a two-hundred day moving average of $22.72. The company has a debt-to-equity ratio of 0.23, a quick ratio of 6.38 and a current ratio of 6.38. The stock has a market capitalization of $5.22 billion, a price-to-earnings ratio of -22.37 and a beta of 0.50. Cogent Biosciences, Inc. has a 52 week low of $3.72 and a 52 week high of $43.73.

Cogent Biosciences (NASDAQ:COGT) last announced its quarterly earnings data on Monday, November 3rd. The technology company reported ($0.50) EPS for the quarter, topping analysts’ consensus estimates of ($0.54) by $0.04. As a group, equities research analysts predict that Cogent Biosciences, Inc. will post -2.42 EPS for the current year.

Wall Street Analysts Forecast Growth

COGT has been the subject of a number of research analyst reports. Leerink Partners boosted their target price on shares of Cogent Biosciences from $18.00 to $50.00 and gave the stock an “outperform” rating in a research note on Monday, November 10th. HC Wainwright raised their price target on shares of Cogent Biosciences to $52.00 and gave the company a “buy” rating in a report on Tuesday, January 6th. Jefferies Financial Group reaffirmed a “buy” rating and set a $48.00 price objective on shares of Cogent Biosciences in a report on Monday, December 8th. Needham & Company LLC reiterated a “hold” rating on shares of Cogent Biosciences in a research report on Monday, December 8th. Finally, UBS Group raised Cogent Biosciences to a “strong-buy” rating in a research note on Wednesday, January 7th. Three investment analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $39.55.

Insider Buying and Selling

In other news, insider John Edward Robinson sold 90,000 shares of the business’s stock in a transaction dated Friday, December 26th. The stock was sold at an average price of $38.74, for a total transaction of $3,486,600.00. Following the completion of the transaction, the insider directly owned 140,002 shares in the company, valued at approximately $5,423,677.48. The trade was a 39.13% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Fairmount Funds Management Llc sold 3,500,000 shares of the company’s stock in a transaction dated Thursday, January 22nd. The shares were sold at an average price of $36.40, for a total value of $127,400,000.00. Following the completion of the sale, the director directly owned 5,503,418 shares of the company’s stock, valued at approximately $200,324,415.20. This trade represents a 38.87% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 3,737,642 shares of company stock worth $136,600,345 in the last ninety days. 7.29% of the stock is currently owned by corporate insiders.

About Cogent Biosciences

Cogent Biosciences is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies that modulate the tumor microenvironment. The company’s research centers on targeting colony-stimulating factor 1 receptor (CSF1R), a key regulator of tumor-associated macrophages that can promote tumor growth and immune evasion. By selectively inhibiting CSF1R, Cogent Biosciences aims to restore immune surveillance and enhance the efficacy of existing cancer treatments.

The company’s lead asset is an orally bioavailable CSF1R inhibitor that has advanced into early-stage clinical trials for various solid tumors.